Today on MedNet21, we're going to discuss Latest Discoveries in Alzheimer’s Disease.
This presentation targets general neurologists as well as family physicians and general practitioners. Given the title, the discussion spans clinical and scientific knowledge. This presentation covers the following areas:
- An overview of AD pathology
- Review of fluid (CSF and blood) biomarkers for AD
- Knowledge of the new biomarker-based definition of the disease which replaces clinical definition in
- A review of the new FDA-approved anti-amyloid treatment aducanumab including its mechanism of action, clinical efficacy, and potential side-effects
- Update on new approaches to biomarker and drug discovery
Dates and Times
End Date: 7/2/2024
ObjectivesAs a result of this educational activity, webcast participants will be able to: Understand the pathology of Alzheimer disease, including the clinical and pathological heterogeneity and the importance of
biomarkers for an accurate diagnosis; Learn about the new FDA-approved anti-amyloid agent aducanumab (approved June 2021).
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.